메뉴 건너뛰기




Volumn 38, Issue 3, 2013, Pages 258-261

Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease

Author keywords

adverse effect; chronic kidney disease; febuxostat; hyperuricaemia; neutropenia

Indexed keywords

ALLOPURINOL; AMLODIPINE; FEBUXOSTAT; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; NIFEDIPINE; OLMESARTAN; SITAGLIPTIN; URIC ACID;

EID: 84876673604     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12057     Document Type: Article
Times cited : (17)

References (19)
  • 1
    • 79551559557 scopus 로고    scopus 로고
    • Clinical practice. Gout
    • Neogi T,. Clinical practice. Gout. N Engl J Med, 2011; 364: 443-452.
    • (2011) N Engl J Med , vol.364 , pp. 443-452
    • Neogi, T.1
  • 2
    • 84869186940 scopus 로고    scopus 로고
    • American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
    • Khanna D, Fitzgerald JD, Khanna PP, et al,. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken), 2012; 64: 1431-1446.
    • (2012) Arthritis Care Res (Hoboken) , vol.64 , pp. 1431-1446
    • Khanna, D.1    Fitzgerald, J.D.2    Khanna, P.P.3
  • 3
    • 0037449776 scopus 로고    scopus 로고
    • An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition
    • Okamoto K, Eger BT, Nishino T, et al,. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem, 2003; 278: 1848-1855.
    • (2003) J Biol Chem , vol.278 , pp. 1848-1855
    • Okamoto, K.1    Eger, B.T.2    Nishino, T.3
  • 4
    • 13444257733 scopus 로고    scopus 로고
    • Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
    • Takano Y, Hase-Aoki K, Horiuchi H, et al,. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005; 76: 1835-1847.
    • (2005) Life Sci , vol.76 , pp. 1835-1847
    • Takano, Y.1    Hase-Aoki, K.2    Horiuchi, H.3
  • 5
    • 17144396355 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment
    • Mayer MD, Khosravan R, Vernillet L, et al,. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther, 2005; 12: 22-34.
    • (2005) Am J Ther , vol.12 , pp. 22-34
    • Mayer, M.D.1    Khosravan, R.2    Vernillet, L.3
  • 6
    • 29644447615 scopus 로고    scopus 로고
    • The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
    • Khosravan R, Grabowski BA, Mayer MD, et al,. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol, 2006; 46: 88-102.
    • (2006) J Clin Pharmacol , vol.46 , pp. 88-102
    • Khosravan, R.1    Grabowski, B.A.2    Mayer, M.D.3
  • 7
    • 81755187321 scopus 로고    scopus 로고
    • A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: Pharmacokinetic and pharmacodynamic study
    • Tatsuo H, Iwao O,. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol, 2011; 17: S27-S34.
    • (2011) J Clin Rheumatol , vol.17
    • Tatsuo, H.1    Iwao, O.2
  • 8
    • 0022358953 scopus 로고
    • Aplastic anemia in a patient with end-stage renal disease caused by allopurinol
    • Matsushita K, Ikegami K, Fukui H,. Aplastic anemia in a patient with end-stage renal disease caused by allopurinol. Nihon Jinzo Gakkai Shi, 1985; 27: 1333-1337.
    • (1985) Nihon Jinzo Gakkai Shi , vol.27 , pp. 1333-1337
    • Matsushita, K.1    Ikegami, K.2    Fukui, H.3
  • 9
    • 64549126581 scopus 로고    scopus 로고
    • Allopurinol-induced aplastic anemia in a patient with chronic kidney disease
    • Kim YW, Park BS, Ryu CH, et al,. Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clin Nephrol, 2009; 71: 203-206.
    • (2009) Clin Nephrol , vol.71 , pp. 203-206
    • Kim, Y.W.1    Park, B.S.2    Ryu, C.H.3
  • 10
    • 74549210268 scopus 로고    scopus 로고
    • Advances in the treatment of neutropenia
    • Dale DC,. Advances in the treatment of neutropenia. Curr Opin Support Palliat Care, 2009; 3: 207-212.
    • (2009) Curr Opin Support Palliat Care , vol.3 , pp. 207-212
    • Dale, D.C.1
  • 11
    • 34248372109 scopus 로고    scopus 로고
    • Systematic review: Agranulocytosis induced by nonchemotherapy drugs
    • Andersohn F, Konzen C, Garbe E,. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med, 2007; 146: 657-665.
    • (2007) Ann Intern Med , vol.146 , pp. 657-665
    • Andersohn, F.1    Konzen, C.2    Garbe, E.3
  • 12
    • 79955050820 scopus 로고    scopus 로고
    • Clinical presentation and management of drug-induced agranulocytosis
    • Andres E, Zimmer J, Mecili M, et al,. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol, 2011; 4: 143-151.
    • (2011) Expert Rev Hematol , vol.4 , pp. 143-151
    • Andres, E.1    Zimmer, J.2    Mecili, M.3
  • 13
    • 0019799332 scopus 로고
    • A method for estimating the probability of adverse drug reactions
    • Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.
    • (1981) Clin Pharmacol Ther , vol.30 , pp. 239-245
    • Naranjo, C.A.1    Busto, U.2    Sellers, E.M.3
  • 14
    • 0029833339 scopus 로고    scopus 로고
    • Immune mechanisms leading to drug-induced blood dyscrasias
    • Claas FH,. Immune mechanisms leading to drug-induced blood dyscrasias. Eur J Haematol Suppl, 1996; 60: 64-68.
    • (1996) Eur J Haematol Suppl , vol.60 , pp. 64-68
    • Claas, F.H.1
  • 15
    • 0035175936 scopus 로고    scopus 로고
    • Genetic determinants of clozapine-induced agranulocytosis: Recent results of HLA subtyping in a non-jewish caucasian sample
    • Dettling M, Cascorbi I, Roots I, et al,. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. Arch Gen Psychiatry, 2001; 58: 93-94.
    • (2001) Arch Gen Psychiatry , vol.58 , pp. 93-94
    • Dettling, M.1    Cascorbi, I.2    Roots, I.3
  • 16
    • 70249122727 scopus 로고    scopus 로고
    • Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
    • Tassaneeyakul W, Jantararoungtong T, Chen P, et al,. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics, 2009; 19: 704-709.
    • (2009) Pharmacogenet Genomics , vol.19 , pp. 704-709
    • Tassaneeyakul, W.1    Jantararoungtong, T.2    Chen, P.3
  • 17
    • 80052596861 scopus 로고    scopus 로고
    • Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis
    • Somkrua R, Eickman EE, Saokaew S, et al,. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet, 2011; 12: 118.
    • (2011) BMC Med Genet , vol.12 , pp. 118
    • Somkrua, R.1    Eickman, E.E.2    Saokaew, S.3
  • 18
    • 34248655834 scopus 로고    scopus 로고
    • Idiosyncratic drug-induced agranulocytosis: Update of an old disorder
    • Andres E, Zimmer J, Affenberger S, et al,. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med, 2006; 17: 529-535.
    • (2006) Eur J Intern Med , vol.17 , pp. 529-535
    • Andres, E.1    Zimmer, J.2    Affenberger, S.3
  • 19
    • 0022339994 scopus 로고
    • Drug-induced agranulocytosis: Evidence for the commitment of bone marrow haematopoiesis
    • Heit W, Heimpel H, Fischer A, et al,. Drug-induced agranulocytosis: evidence for the commitment of bone marrow haematopoiesis. Scand J Haematol, 1985; 35: 459-468.
    • (1985) Scand J Haematol , vol.35 , pp. 459-468
    • Heit, W.1    Heimpel, H.2    Fischer, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.